Cavano Capital operates like a lab: technical and thesis‑driven.
We design around clinical milestones and manufacturing plans from day one.
Building in biotech is difficult. The timelines are long, the regulatory environment is unforgiving, and the science can be wrong even when the founder is right.
Cavano Capital invests early precisely because that difficulty is understood. There will be moments of negative data, regulatory setbacks and pressure from every direction. That is when founders deserve capital that does not flinch. With Cavano Capital, that investment will always come with honesty and genuine respect for the path chosen.
Cavano Capital was built across two. With offices in Singapore and Copenhagen, the fund focuses on founders whose work touches HSA or EMA environments. We underwrite the complexity of both regulatory paths from the start, so teams can plan trials and market access for multi‑region entry instead of locking into a single market too early.
Dense clinical trial infrastructure and nationally backed research ecosystems make Singapore an ideal base for early human data. Active bio-security policy creates a strong pull for bio-industrial platforms aligned with food and health mandates.
1 Raffles PI, Singapore 048616, Singapore
Copenhagen carries decades of expertise in metabolic disease, CNS and biologics. The region generates a strong pipeline of defensible IP that frequently needs new vehicles and cross-border capital to reach its potential.
Pasteurs Tower, Fadet 6, 1799 Copenhagen, Denmark